Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_0047 |
Primary information | |
---|---|
B3PDB ID | b3pdb_0047 |
Peptide Name | C-TN-APNPs |
PEPTIDE SEQUENCE (1-letter) | CAQK |
PEPTIDE SEQUENCE (3-letter) | CysAlaGlnLys |
N-terminal modification | NA |
C-terminal modification | NA |
Chemical modification | NA |
Peptide Length | 4 |
Conformation | Linear |
Peptide Nature | NA |
Source/Origin of peptide | Chemically synthesized |
SMILES | N[C@@]([H])(CS)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCCN)C(=O)O |
Cell Line | hCMEC/D3 and NHA cells |
In vitro CONCENTRATION | NA |
In vitro METHOD | TEM imaging |
In vitro RESULT | Responsive to thrombin cleavage, reduced the cytotoxicity of Tat-NR2B9c, and increased BBB permeabil |
ANIMAL MODEL | C57BL6 mice |
In vivo CONCENTRATION | NA |
In vivo MODE OF DELIVERY | Intravenous |
In vivo METHOD | Dynamic light scattering |
In vivo RESULT | Better circulation time, better targeting ability and penetrating efficiency to the injured brain, a |
ACTION | Treatment reduced the injury size |
TRANSPORT TYPE | NA |
SUBCELLULAR LOCALISATION | NA |
COMBINATION | Combined with Tat-NR2B9c |
PHYSICAL CONDITION | Traumatic brain injury |
RESPONSE | NA |
RESULT | NA |
LABEL | NA |
PMID | 31213815 |